Last reviewed · How we verify
Ticlopidine + Ginko biloba
Ticlopidine + Ginko biloba is a antiplatelet Small molecule drug developed by Samsung Medical Center. It is currently in Phase 3 development for Prevention of stroke in patients with atherosclerotic disease. Also known as: Yuclid.
Ticlopidine inhibits platelet aggregation by irreversibly blocking ADP receptors on platelets, while Ginkgo biloba has antioxidant and anti-inflammatory properties.
Ticlopidine inhibits platelet aggregation by irreversibly blocking ADP receptors on platelets, while Ginkgo biloba has antioxidant and anti-inflammatory properties. Used for Prevention of stroke in patients with atherosclerotic disease.
At a glance
| Generic name | Ticlopidine + Ginko biloba |
|---|---|
| Also known as | Yuclid |
| Sponsor | Samsung Medical Center |
| Drug class | antiplatelet |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Ticlopidine works by binding to the P2Y12 receptor on platelets, preventing ADP from binding and activating the receptor. This leads to a decrease in platelet aggregation and a subsequent reduction in the risk of thrombotic events. Ginkgo biloba, on the other hand, has been shown to have antioxidant and anti-inflammatory properties, which may contribute to its potential therapeutic effects.
Approved indications
- Prevention of stroke in patients with atherosclerotic disease
Common side effects
- Thrombocytopenia
- Neutropenia
- Diarrhea
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ticlopidine + Ginko biloba CI brief — competitive landscape report
- Ticlopidine + Ginko biloba updates RSS · CI watch RSS
- Samsung Medical Center portfolio CI
Frequently asked questions about Ticlopidine + Ginko biloba
What is Ticlopidine + Ginko biloba?
How does Ticlopidine + Ginko biloba work?
What is Ticlopidine + Ginko biloba used for?
Who makes Ticlopidine + Ginko biloba?
Is Ticlopidine + Ginko biloba also known as anything else?
What drug class is Ticlopidine + Ginko biloba in?
What development phase is Ticlopidine + Ginko biloba in?
What are the side effects of Ticlopidine + Ginko biloba?
What does Ticlopidine + Ginko biloba target?
Related
- Drug class: All antiplatelet drugs
- Target: All drugs targeting P2Y12 receptor
- Manufacturer: Samsung Medical Center — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Prevention of stroke in patients with atherosclerotic disease
- Also known as: Yuclid
- Compare: Ticlopidine + Ginko biloba vs similar drugs
- Pricing: Ticlopidine + Ginko biloba cost, discount & access